Compare Elder Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ASTRAZENECA PHARMA ELDER PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x -0.2 81.8 - View Chart
P/BV x 0.1 23.0 0.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ASTRAZENECA PHARMA
Mar-18
ELDER PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,278 29.7%   
Low Rs188883 21.3%   
Sales per share (Unadj.) Rs491.2228.4 215.1%  
Earnings per share (Unadj.) Rs-3.210.4 -30.7%  
Cash flow per share (Unadj.) Rs14.416.3 88.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.598.8 381.2%  
Shares outstanding (eoy) m20.5425.00 82.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.7 12.2%   
Avg P/E ratio x-89.3104.2 -85.6%  
P/CF ratio (eoy) x19.766.4 29.7%  
Price / Book Value ratio x0.810.9 6.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,83327,008 21.6%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m2,1791,535 141.9%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m10,0895,710 176.7%  
Other income Rs m257123 209.5%   
Total revenues Rs m10,3465,833 177.4%   
Gross profit Rs m-792463 -171.1%  
Depreciation Rs m361147 245.1%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,653438 -834.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125179 70.0%   
Profit after tax Rs m-65259 -25.2%  
Gross profit margin %-7.88.1 -96.8%  
Effective tax rate %-3.440.8 -8.4%   
Net profit margin %-0.64.5 -14.3%  
BALANCE SHEET DATA
Current assets Rs m9,2403,209 287.9%   
Current liabilities Rs m9,9982,070 483.1%   
Net working cap to sales %-7.520.0 -37.6%  
Current ratio x0.91.6 59.6%  
Inventory Days Days4672 64.0%  
Debtors Days Days6035 171.6%  
Net fixed assets Rs m10,124790 1,281.0%   
Share capital Rs m20650 411.4%   
"Free" reserves Rs m5,5822,419 230.7%   
Net worth Rs m7,7342,469 313.2%   
Long term debt Rs m4,8890-   
Total assets Rs m22,8824,605 496.9%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.2 35.6%   
Return on assets %11.85.6 209.0%  
Return on equity %-0.810.5 -8.1%  
Return on capital %22.317.7 125.8%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m307300 102.4%   
Fx outflow Rs m1252,015 6.2%   
Net fx Rs m181-1,715 -10.6%   
CASH FLOW
From Operations Rs m11,75488 13,372.1%  
From Investments Rs m-561-94 598.8%  
From Financial Activity Rs m-6,762NA-  
Net Cashflow Rs m4,432-6 -77,749.1%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 16.8 15.7 107.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 9.1 396.7%  
Shareholders   16,479 12,856 128.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  WYETH LTD  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - DISHMAN PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS